|
o-Xylene | CAS 95-47-6 | ||
C6H4(CH3)2 | RTECS ZE2450000 | ||
Synonyms & Trade Names 1,2-Dimethylbenzene; ortho-Xylene; o-Xylol |
DOT ID & Guide 1307 130 |
Exposure Limits |
NIOSH REL: TWA 100 ppm (435 mg/m3) ST 150 ppm (655 mg/m3) | ||
OSHA PEL�: TWA 100 ppm (435 mg/m3) | |||
IDLH 900 ppm | Conversion 1 ppm = 4.34 mg/m3 |
Physical Description Colorless liquid with an aromatic odor. |
|||
MW: 106.2 |
BP: 292°F |
FRZ: -13°F |
Sol: 0.02% |
VP: 7 mmHg |
IP: 8.56 eV |
|
Sp.Gr: 0.88 |
Fl.P: 90°F |
UEL: 6.7% |
LEL: 0.9% |
|
Class IC Flammable Liquid: Fl.P. at or above 73�F and below 100�F. | |||
Incompatibilities & Reactivities Strong oxidizers, strong acids |
Measurement Methods NIOSH 1501, 3800; OSHA 1002 |
Personal Protection & Sanitation Skin: Prevent skin contact Eyes: Prevent eye contact Wash skin: When contaminated Remove: When wet (flammable) Change: No recommendation |
First Aid (See procedures) Eye: Irrigate immediately Skin: Soap wash promptly Breathing: Respiratory support Swallow: Medical attention immediately |
Respirator Recommendations
NIOSH/OSHA Up to 900 ppm: (APF = 10) Any chemical cartridge respirator with organic vapor cartridge(s)*/(APF = 25) Any powered, air-purifying respirator with organic vapor cartridge(s)*/(APF = 10) Any supplied-air respirator*/(APF = 50) Any self-contained breathing apparatus with a full facepiece Emergency or planned entry into unknown concentrations or IDLH conditions: (APF = 10,000) Any self-contained breathing apparatus that has a full facepiece and is operated in a pressure-demand or other positive-pressure mode/(APF = 10,000) Any supplied-air respirator that has a full facepiece and is operated in a pressure-demand or other positive-pressure mode in combination with an auxiliary self-contained positive-pressure breathing apparatus Escape: (APF = 50) Any air-purifying, full-facepiece respirator (gas mask) with a chin-style, front- or back-mounted organic vapor canister/Any appropriate escape-type, self-contained breathing apparatus |
|
Exposure Routes inhalation, skin absorption, ingestion, skin and/or eye contact | |
Symptoms Irritation eyes, skin, nose, throat; dizziness, excitement, drowsiness, incoordination, staggering gait; corneal vacuolization; anorexia, nausea, vomiting, abdominal pain; dermatitis | |
Target Organs
Eyes, skin, respiratory system, central nervous system, gastrointestinal tract, blood, liver, kidneys |
See also: INTRODUCTION |